13- CV J.Favier

Judith Favier

Inserm Research Director (DR1)

TEAM LEADER – GENETICS AND METABOLISM OF RARE CANCERS

Mail : judith.favier@inserm.fr

PHONE :+33 1 53 98 80 41

SCIENTIFIC TOPICS

Paraganglioma, Pheochromocytoma, renal cancer
Metabolism, Genetics, Epigenetics

ITMO

Cancer

Biosketch

After a PhD training in the Collège de France (Paris) and a post-doc at the Montreal Heart Institute focused on the study of HIF2alpha and its role in angiogenesis, I have been recruited by Inserm in 2007. I now lead a research team at the Paris-Cardiovascular Research Centre of the Georges Pompidou Hospital (HEGP) in Paris dedicated to the study of the genetics and biology of rare cancers, and in particular pheochromocytomas and paragangliomas. our research activity mainly focuses on inherited forms caused by mutations in genes encoding the mitochondrial enzyme sucinate dehydrogenase (SDH) and their role in pseudo-hypoxia, epithelial-to mesenchymal transition and epigenetic modifications.

Academic position

2022: Research Director class 1 (DR1 Inserm)

2019: Team Leader, Inserm team “Genetics and Metabolism of Rare Cancers”– PARCC-HEGP

2014-2021: Research Director (DR2 Inserm)

2014-2018: co-Team Leader– PARCC-HEGP

2011-2014: Senior Researcher (CR1 Inserm) –

2009: Group leader of the “PPGL” group – PARCC-HEGP, Paris

2007-2011: Junior Researcher (CR2 Inserm) – Collège de France and PARCC-HEGP

Responsabilities and activities

2024-2026: Vice-President of the French Society of Endoctinomogy (SFE)

2023-now: Deputy director of the SIRIC CARPEM

2023-now: Member of the Tumor genetics commission (CN2) from the ARC Foundation

2021-now: Head of the PPGL working group of ENS@T

2018-now: Associate Editor at Endocrine-related Cancer

2018-2021: Elected member of the PPGL working group of ENS@T

2017-2021: Member of the Scientific comitee of the French Society of Endocrinology (SFE)

2016-2021: Member of INSERM commission CSS2

2015-now: Co-chair of the Pheochromocytoma Research Support Organization (PRESSOR).

2015-now: Member of the “Rare Cancers” working group from the Cancéropôle Ile de France

2010-now: Member of the European Network for the Study of Adrenal Tumors (ENS@T)

2009-now: Co-Chairman of the «Animals models» working group from PRESSOR.

Awards

2022: Doctoral and Research Supervision award INSERM

2017: Doctoral and Research Supervision award INSERM

2013: Prize of Scientific Excellence INSERM

2012: French National Research Agency, Young Investigator award

2002: Young Researchers award (Fondation Bettencourt-Schueller)

Scientific summary

Our team is interested in rare cancers in which we investigate fundamental mechanisms linking genetic disorders to energy metabolism, angiogenesis, epigenetic reprogramming and carcinogenesis. It is composed of biologists and clinicians involved in the management of patients at different levels (genetics, urology, pathology, hypertension, oncology and nuclear medicine). We address fundamental questions through the study of oncogenic pathways associated with mitochondrial dysfunction and develop translational research projects through human genetics, biomarker identification and validation, as well as proof-of-concept studies for new therapeutics.